| CAS No. | 98327-87-8 |
| Molecular Formula | C44H32P2 |
| Molecular Weight | 622.67 g/mol |
| Category | Pharmacopoeial Impurity Standards / EP Impurities |
| Availability | In Stock |
The occurrence of Brexpiprazole Impurity 33 is closely related to organophosphorus functionality, a polycyclic aromatic system in its molecular formula, which determines its behaviour during synthesis, purification, or degradation.
As a process- or degradation-related impurity, Brexpiprazole Impurity 33 (CAS 98327-87-8, C44H32P2) is essential for impurity profiling, related-substances testing, and forced-degradation studies in pharmaceutical development.
Owing to organophosphorus functionality, a polycyclic aromatic system, Brexpiprazole Impurity 33 is typically pale yellow to yellow amorphous powder. Its solid-state physicochemical attributes — including a molecular weight of 622.67 g/mol — guide the selection of appropriate sample preparation and analytical techniques. The high carbon-to-hydrogen ratio imparts good lipophilicity, allowing liquid-liquid extraction with non-polar solvents such as n-hexane or ethyl acetate.
This reference standard supports related-substances testing and method development in line with ICH Q3A/Q3B guidance on impurity control, and is suitable for system suitability testing and forced-degradation studies.
As a certified reference material (CRM), Brexpiprazole Impurity 33 meets the metrological traceability requirements of ISO/IEC 17025 laboratories. Batch-to-batch consistency is monitored via control charts to guarantee comparable assigned values across lots.
| Molecular Formula | C44H32P2 |
| Molecular Weight | 622.67 g/mol |
| Purity | 97%+ |
| Storage | Store at room temperature, protect from light |
| Solubility (reference) | Soluble in chloroform, dichloromethane, ethyl acetate |
| Stability | Light-sensitive; avoid direct strong light |
| Degree of Unsaturation (DBE) | 29.0 |
| UV Absorption | UV-absorbing |
| Structural Features | Aromatic ring present |
| CAS Registry Year (est.) | 1985 |